Brief: Mesoblast Says Ryoncil Sales For Quarter Increase 60% To $35.1M
09/01/2026 02:18
Jan 9 (Reuters) - Mesoblast Ltd MSB.AX: RYONCIL SALES FOR QUARTER INCREASE 60% TO US$35.1M Further company coverage: MSB.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mesoblast
See all newsBrief: Mesoblast William Burns To Retire From Board At 2026 AGM
Brief: Mesoblast Says Q1 Net Revenues Up 44%
Australia's Mesoblast hits one-month high on upbeat quarterly update
Australia's Mesoblast drops as Bell Potter cuts target price after key drug misses sales view
Brief: Mesoblast Says FDA Approves New Potency Assay For Commercial Ryoncil